OnCo
companiesCompany

Puma Biotechnology

Puma Biotechnology developed neratinib (Nerlynx), the extended-adjuvant HER2 pill.

Single-product company; neratinib approved 2017 (extended adjuvant) and 2020 (metastatic with capecitabine); also alisertib (Aurora A) in development.

Headquarters
Los Angeles, CA, US
Type
biotech · PBYI

Products

1top
ApprovedSmall-molecule irreversible pan-HER kinase inhibitor
Neratinib · Nerlynx

A pill taken for a year after trastuzumab to further reduce recurrence in HER2-positive, hormone-positive breast cancer, limited by severe diarrhoea.

Connected

3top

Pages like this

not linked directly; found by shared links

cancers

1
HER2-positive breast cancer

fronts

1
Targeted Therapy

drugs

1
ApprovedSmall-molecule irreversible pan-HER kinase inhibitor
Neratinib · Nerlynx